Access Pharmaceuticals, Inc. engages in the development of polymer linked cytotoxics for use in the treatment of cancer and other diseases states utilizing proprietary delivery technologies. The company’s lead product AP5346, which is in phase II clinical development, is a polymer of DACH-platinum, the active principal of oxaliplatin. It also has other drug delivery technologies, including vitamin-mediated targeted delivery and oral care drug delivery. The company has proprietary patents to four drug delivery technology platforms: synthetic polymer targeted delivery, vitamin mediated targeted delivery, vitamin mediated oral delivery, and mucoadhesive liquid technology. Access Pharmaceuticals was founded in 1988 and is headquartered in Dallas, Texas.